Breaking News Instant updates and real-time market news.

MNTA

Momenta

$13.90

-0.25 (-1.77%)

, ABBV

AbbVie

$61.53

2.07 (3.48%)

13:08
11/29/16
11/29
13:08
11/29/16
13:08

Question on Momenta's biosimilar Humira not efficacy, but legality, says Maxim

Maxim analyst Jason McCarthy noted that Momenta (MNTA) announced that M923, its biosimilar version of Humira, met the primary endpoint in a trial of its efficacy, but added that the question about the product "is not efficacy, it is legal." If M923 is approved, a fight over IP with AbbVie (ABBV) could delay the commercial launch to 2022 or later, said McCarthy, who keeps a Sell rating on Momenta shares.

MNTA

Momenta

$13.90

-0.25 (-1.77%)

ABBV

AbbVie

$61.53

2.07 (3.48%)

  • 03

    Dec

  • 05

    Dec

MNTA Momenta
$13.90

-0.25 (-1.77%)

09/07/16
MAXM
09/07/16
DOWNGRADE
MAXM
Sell
Momenta downgraded to Sell from Hold at Maxim
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.
11/22/16
AGIS
11/22/16
INITIATION
Target $15
AGIS
Hold
Momenta initiated with a Hold at Aegis
Aegis analyst Difei Yang iniatied Momenta with a Hold and a $15 price target.
11/29/16
MAXM
11/29/16
NO CHANGE
Target $6
MAXM
Sell
Momenta launch of Humira biosimilar could be delayed, says Maxim
Maxim analyst Jason McCarthy continues to believe that Momenta Pharmaceuticals' launch of M923, a biosimilar of Humira, could be delayed after the company said a Phase III study met its endpoint. The results are not a surprise as the question is not efficacy, it is legal, McCarthy tells investors in a research note. He believes Momenta put too much emphasis on "science/technology" when it comes to biosimilars and not enough on intellectual property. McCarthy keeps a Sell rating on Momenta shares with a $6 price target. The stock is up 30c to $14.20 in afternoon trading.
ABBV AbbVie
$61.53

2.07 (3.48%)

11/08/16
BARD
11/08/16
NO CHANGE
Target $40
BARD
Outperform
Coherus Biosciences weakness a buying opportunity, says Baird
Baird analyst Michael Ulz noted Coherus (CHRS) received a decision denying the institution of the '166 IPR related to Abbie's (ABBV) Humira. Though the decision was disappointing, the analyst sees multiple opportunities remaining to circumvent the patent. Ulz said he would be a buyer on the weakness in Coherus and reiterated his Outperform rating and $40 price target on the shares.
11/28/16
SBSH
11/28/16
DOWNGRADE
SBSH
Neutral
AbbVie downgraded to Neutral from Buy at Citi
11/28/16
SBSH
11/28/16
DOWNGRADE
Target $60
SBSH
Neutral
Citi analyst 'perturbed,' downgrades AbbVie to Neutral
Citi analyst Andrew Baum earlier today downgraded AbbVie (ABBV) to Neutral from Buy and lowered his price target for the shares to $60 from $65. The biopharmaceutical company is trading down 2%, or 99c, to $59.52. The risk to post 2017 consensus estimates for Humira has "increased on almost all fronts," Baum tells investors in a research note. The analyst sees increased patent risk and competition from biosimilar Enbrel in Europe. He also believes AstraZeneca (AZN) and Acerta's acalabrutinib "looks like a better mousetrap" than AbbVie's Imbruvica. Baum is also "perturbed" by AbbVie management's recent "rich" acquisition of Stemcentrx. He prefers shares of Eli Lilly (LLY) and Bristol-Myers (BMY) to AbbVie.
11/28/16
11/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AbbVie (ABBV) downgraded to Neutral from Buy at Citi. 2. Citi (C), Wells Fargo (WFC), and Regions Financial (RF) were downgraded to Hold from Buy at Jefferies with analyst Ken Usdin citing valuation. 3. Hilton (HLT) and Marriott (MAR) were downgraded to Hold from Buy at Evercore ISI. 4. H&R Block (HRB) downgraded to Sell from Neutral at BTIG with analyst Mark Palmer noting that President-elect Trump has said he wants to put H&R Block out of business by simplifying the tax code. 5. Tupperware Brands (TUP) downgraded to Sell from Neutral at B. Riley with analyst Linda Bolton Weiser saying the stock has not moved lower to reflect post-election currency devaluations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

GS

Goldman Sachs

$249.02

1.67 (0.68%)

, TAL

TAL Education

$85.58

0.33 (0.39%)

13:51
02/27/17
02/27
13:51
02/27/17
13:51
Hot Stocks
Breaking Hot Stocks news story on Goldman Sachs, TAL Education »

Goldman Sachs reports…

GS

Goldman Sachs

$249.02

1.67 (0.68%)

TAL

TAL Education

$85.58

0.33 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 03

    Mar

MYGN

Myriad Genetics

$18.98

-0.07 (-0.37%)

, VCYT

Veracyte

$7.95

0.06 (0.76%)

13:50
02/27/17
02/27
13:50
02/27/17
13:50
Recommendations
Myriad Genetics, Veracyte analyst commentary  »

Piper sees CMS halt of…

MYGN

Myriad Genetics

$18.98

-0.07 (-0.37%)

VCYT

Veracyte

$7.95

0.06 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

13:50
02/27/17
02/27
13:50
02/27/17
13:50
General news
Treasury Action: yield have spiked higher as rate hike fears flare up »

Treasury Action: yield…

LJPC

La Jolla

$19.87

1.65 (9.06%)

13:39
02/27/17
02/27
13:39
02/27/17
13:39
Recommendations
La Jolla price target raised to $40 from $27 at Jefferies »

Jefferies analyst Eun…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 19

    Mar

NH

NantHealth

$7.54

-0.08 (-1.05%)

, MDRX

Allscripts

$12.05

-0.11 (-0.90%)

13:33
02/27/17
02/27
13:33
02/27/17
13:33
Hot Stocks
CTCA partners with Allscripts, NantHealth to launch Clinical Pathways »

Cancer Treatment Centers…

NH

NantHealth

$7.54

-0.08 (-1.05%)

MDRX

Allscripts

$12.05

-0.11 (-0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

VRAY

ViewRay

$4.76

0.01 (0.21%)

13:30
02/27/17
02/27
13:30
02/27/17
13:30
Recommendations
ViewRay analyst commentary  »

ViewRay price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 06

    Mar

AIG

AIG

$63.97

0.34 (0.53%)

13:29
02/27/17
02/27
13:29
02/27/17
13:29
Periodicals
AIG board to discuss whether to penalize or oust CEO over Q4 numbers, WSJ says »

AIG's directors are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

HAIN

Hain Celestial

$34.61

-0.23 (-0.66%)

13:26
02/27/17
02/27
13:26
02/27/17
13:26
Options
Hain Celestial call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$82.00

3.7 (4.73%)

13:19
02/27/17
02/27
13:19
02/27/17
13:19
Downgrade
bluebird bio rating change  »

Follow-up: bluebird bio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

$NSD

NASDAQ Market Internals

13:17
02/27/17
02/27
13:17
02/27/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
02/27/17
02/27
13:16
02/27/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$82.00

3.7 (4.73%)

13:15
02/27/17
02/27
13:15
02/27/17
13:15
Downgrade
bluebird bio rating change  »

bluebird bio downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

STM

STMicroelectronics

$15.49

0.485 (3.23%)

13:06
02/27/17
02/27
13:06
02/27/17
13:06
Options
STMicroelectronics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$81.47

0.385 (0.47%)

13:05
02/27/17
02/27
13:05
02/27/17
13:05
Periodicals
Exxon CEO sees rising Permian production, continued Russia presence, Forbes says »

Speaking in a Forbes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Mar

SAFM

Sanderson Farms

$94.44

-0.72 (-0.76%)

13:01
02/27/17
02/27
13:01
02/27/17
13:01
Conference/Events
Sanderson Farms management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

DDAIF

Daimler AG

$72.92

-0.39 (-0.53%)

13:01
02/27/17
02/27
13:01
02/27/17
13:01
Hot Stocks
Daimler names Martin Daum head of Trucks, Buses divisions »

Daimler said its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$186.67

-0.7399 (-0.39%)

13:00
02/27/17
02/27
13:00
02/27/17
13:00
Hot Stocks
IPTAB upholds validity of 3M Korean patent »

The Intellectual Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRVG

trivago

$12.85

-0.13 (-1.00%)

12:57
02/27/17
02/27
12:57
02/27/17
12:57
Conference/Events
trivago management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

SSNLF

Samsung

, FB

Facebook

$135.44

0.08 (0.06%)

12:55
02/27/17
02/27
12:55
02/27/17
12:55
Hot Stocks
Samsung says new Facebook app available for Samsung TVs »

Samsung (SSNLF) announced…

SSNLF

Samsung

FB

Facebook

$135.44

0.08 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 06

    Mar

  • 19

    Mar

  • 28

    Mar

SNAP

Snap Inc.

12:52
02/27/17
02/27
12:52
02/27/17
12:52
Hot Stocks
Snap Inc: Some Class A shares subject to separate lock-up »

In an amended IPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

MRVL

Marvell

12:51
02/27/17
02/27
12:51
02/27/17
12:51
Options
Notable premium seller in Marvell Tech »

Notable premium seller in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 10

    Mar

  • 04

    Apr

  • 05

    Apr

WLL

Whiting Petroleum

$10.95

0.15 (1.39%)

12:46
02/27/17
02/27
12:46
02/27/17
12:46
Options
Whiting Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

CLSD

Clearside Biomedical

$8.06

1.16 (16.81%)

12:45
02/27/17
02/27
12:45
02/27/17
12:45
Conference/Events
Clearside Biomedical has a conference call hosted by JPMorgan »

JPMorgan Analyst Rama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SBGSY

Schneider Electric

$13.49

-0.21 (-1.53%)

12:44
02/27/17
02/27
12:44
02/27/17
12:44
Conference/Events
Schneider Electric management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 02

    Mar

  • 03

    Mar

MTB

M&T Bank

$168.14

-0.535 (-0.32%)

12:37
02/27/17
02/27
12:37
02/27/17
12:37
Hot Stocks
M&T Bank announces passing of COO Mark Czarnecki »

M&T Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.